Special Cases

Chapter 15: Special Cases in Prostate Cancer

Opening Story

Marco was 44 years old when his doctor told him he had prostate cancer. "But I'm too young for this," he said. His wife was pregnant with their second child. His mind raced — not just about the cancer, but about fertility, about decades of potential side effects, about whether his sons would face the same diagnosis someday. Marco's story is a reminder that prostate cancer does not follow a single script. Every patient brings a unique set of circumstances — age, anatomy, medical history, identity — that shapes how the disease is managed. This chapter is about those special circumstances.

Part 1: Young Men with Prostate Cancer

Most prostate cancers are diagnosed in men in their 60s and 70s. But roughly 1–4.5% of cases occur in men under 50, and the incidence in younger men has been increasing globally at approximately 2% per year since 1990.¹ ² A recent SEER analysis confirmed that prostate cancer incidence in men under 55 has risen substantially over the past five decades, though mortality in this age group has remained stable.³

What makes young men different?

Young men with prostate cancer face a unique set of challenges:

• Longer life expectancy means treatment side effects — erectile dysfunction, urinary incontinence, bowel changes — must be endured for decades, not years.
• Fertility preservation is critical. Sperm banking should be discussed before any treatment, especially before radiation or hormone therapy. Even surgery can affect ejaculation.
• Career and family impact. A cancer diagnosis in your 40s hits differently than in your 70s. Work disruptions, insurance concerns, and the emotional toll on young families are significant.
• Biology may differ. Some studies suggest younger men present with more aggressive disease, while others show favorable pathology. A meta-analysis of localized prostate cancer in men ≤50 years treated with radical prostatectomy found that younger men had lower rates of extracapsular extension and seminal vesicle invasion compared to older men, suggesting favorable pathology in the PSA era.⁴ However, worldwide data show that men aged 15–40 are more than 6 times more likely to have distant disease at diagnosis than older men.² Among men with low-risk disease, active surveillance rates have quadrupled from 2010 to 2015, with 5-year prostate cancer-specific mortality below 0.30% regardless of management approach.⁵
• Genetic testing is especially important. Younger men are more likely to carry hereditary mutations such as BRCA2, BRCA1, or [Lynch syndrome](/rare-disease/lynch-syndrome) genes. The NCCN recommends that individuals with known or suspected cancer susceptibility genes be referred to a cancer genetics professional. If a young man is diagnosed, his brothers and sons should be informed about earlier screening — typically starting at age 40 rather than 45.⁶
• Autopsy studies show that about 20–30% of men aged 40–50 harbor microscopic prostate cancer, most of which would never cause symptoms or death.⁷ This underscores the importance of not overtreating low-risk disease in young men.

Treatment considerations:

There is no single "best" treatment for young men. The decision depends on risk group, anatomy, and personal priorities. Active surveillance is appropriate for low-risk disease even in younger men, though national data show some ambivalence — younger men are still less likely to choose surveillance than older men with identical disease.⁵ When treatment is needed, both surgery and radiation offer excellent long-term cancer control, but the side effect profiles differ and must be weighed against decades of survivorship.

Part 2: Older Men with Prostate Cancer

On the other end of the spectrum, many men are diagnosed with prostate cancer in their 70s and 80s. For these men, the critical question is not just "What is my cancer risk?" but "What else might affect my lifespan?"

Competing risks: dying WITH prostate cancer vs. FROM prostate cancer

A comprehensive review of untreated prostate cancer found that men diagnosed after age 75 faced substantial competing mortality — approximately 57–60% died of non-cancer causes within 10 years, regardless of tumor grade.⁸ A population-based study of incidental prostate cancer confirmed that other-cause mortality substantially exceeded cancer-specific mortality across all Gleason categories in men who were not actively treated.⁹

Life expectancy estimation matters more than age alone.

A healthy, active 78-year-old may have a longer life expectancy than a sedentary 65-year-old with diabetes and heart failure. The NCCN emphasizes that life expectancy — not age — is the key determinant for treatment decisions.¹⁰ Tools such as the Charlson Comorbidity Index and life expectancy calculators help doctors estimate how long a patient is likely to live, which directly influences whether aggressive treatment is warranted.

When observation is the best choice:

For men with limited life expectancy (generally less than 5–10 years depending on risk group), observation — also called watchful waiting — may be the most appropriate approach. This means monitoring symptoms and treating only if the cancer causes problems, rather than pursuing cure. The goal is to maintain quality of life and avoid the side effects of treatment that the patient may never benefit from.

Geriatric oncology assessment:

Older patients benefit from a comprehensive geriatric assessment that evaluates not just the cancer, but also functional status, cognitive function, nutritional status, social support, and medication burden. This helps the care team tailor treatment intensity to the individual.

Balancing family pressure with realistic goals:

Families often push for aggressive treatment — "Do everything, doctor." This is understandable, but it is important to have honest conversations about what treatment can and cannot achieve. In some cases, the side effects of treatment (incontinence, fatigue, falls from hormone therapy) may cause more harm than the cancer itself.

Part 3: Prostate Cancer After Prior TURP

What is TURP?

Transurethral resection of the prostate (TURP) is a common surgical procedure for benign prostatic hyperplasia (BPH). It involves removing the inner portion of the prostate through the urethra, creating a cavity — essentially "hollowing out" the prostate to relieve urinary obstruction.

How TURP changes the treatment landscape:

• Brachytherapy (seed implants): A prior TURP is a relative contraindication to low-dose rate (LDR) brachytherapy because the cavity created by TURP can lead to uneven seed distribution, increased urinary side effects, and a higher risk of incontinence. The NCCN advises that providers should consider prior TURP as a factor that may increase the risk of adverse effects from brachytherapy. However, high-dose rate (HDR) brachytherapy may be safer in this setting because its inverse planning allows better dose optimization around the cavity.¹⁰
• External beam radiation (EBRT): Modern techniques such as IMRT and SBRT appear to be reasonably well tolerated in post-TURP patients, though careful planning is essential. Rectal dose constraints and urethral dose optimization are particularly important.
• Surgery (radical prostatectomy): Prior TURP can make surgery more challenging due to altered anatomy and scarring. Some studies report a higher risk of incontinence after prostatectomy in men with prior TURP.
• Incidental cancer found at TURP: Sometimes prostate cancer is discovered unexpectedly in the tissue removed during TURP. These are classified as T1a (less than 5% of tissue is cancer, low grade) or T1b (more than 5% or higher grade). Management depends on the amount and grade of cancer found, the patient's age, and life expectancy.

Key takeaway: A prior TURP does not prevent you from receiving radiation or surgery, but it does require special planning and an experienced team.

Part 4: Prostate Cancer in Men Without a Rectum

Some men have had their rectum surgically removed — most commonly due to rectal cancer (abdominoperineal resection, or APR), inflammatory bowel disease surgery, or trauma.

Impact on diagnosis:

• Transrectal ultrasound and transrectal biopsy are not possible. The transperineal approach (through the skin between the scrotum and anus) is used instead.
• Digital rectal exam cannot be performed.

Impact on radiation therapy:

• Rectal spacers (hydrogel placed between the prostate and rectum to protect the rectum from radiation) cannot be used.
• The anatomy is altered — bowel loops may fill the space where the rectum used to be, potentially increasing the risk of bowel toxicity from radiation.
• Dose constraints must be carefully adjusted for the altered anatomy.
• LDR brachytherapy is absolutely contraindicated in the absence of a rectum, as the transrectal ultrasound guidance used during the procedure requires a rectum.¹⁰

Impact on surgery:

• Prior pelvic surgery creates adhesions and altered tissue planes, making radical prostatectomy more technically challenging.

Key takeaway: Men without a rectum can still be treated for prostate cancer, but the approach requires careful multidisciplinary coordination and an experienced team familiar with altered pelvic anatomy.

Part 5: Prostate Cancer and Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease — Crohn's disease and ulcerative colitis — has historically been considered a relative contraindication to pelvic radiation therapy due to concerns about worsening bowel inflammation and toxicity. Recent evidence also suggests that men with IBD may be at increased risk of prostate cancer itself. A large UK Biobank study of over 218,000 men found that IBD — particularly ulcerative colitis — was associated with a 31% increased risk of prostate cancer (HR 1.31).¹¹ A single-institution matched cohort study found an even stronger association, with 10-year prostate cancer incidence of 4.4% in IBD patients versus 0.65% in controls (HR 4.84).¹²

What does the evidence show about treatment safety?

• A Veterans Affairs multicenter study of 100 IBD patients with prostate cancer found that radiation-treated patients had 2-fold higher rates of IBD flares within the first year (10.6% vs. 5.7%), but there were no differences in IBD-related hospitalizations or surgeries. The authors concluded that avoidance of radiation therapy in IBD patients is likely not necessary.¹³
• Modern radiation techniques appear to mitigate risk. A study of 31 IBD patients treated with SBRT for prostate cancer found that high-grade toxicity was rare (only 1 patient with grade 3 proctitis), and the authors concluded that modern radiation techniques appear to have mitigated the risk of GI side effects.¹⁴
• A large National Inpatient Sample analysis of over 251,000 radical prostatectomy patients found that both Crohn's disease and ulcerative colitis were associated with higher rates of adverse in-hospital outcomes after surgery, with Crohn's disease appearing to carry a somewhat higher complication risk than ulcerative colitis. Minimally invasive surgery was associated with fewer adverse outcomes than open surgery in both IBD subgroups.¹⁵
• The AGA Clinical Practice Update (2024) notes that IBD medications — including anti-TNF agents, vedolizumab, and ustekinumab — are not associated with a significant increased risk of incident cancer in patients with IBD and a history of prior cancer.¹⁶

Practical guidance:

• IBD should be well controlled before starting any cancer treatment.
• Gastroenterology coordination is essential — IBD medications may need adjustment.
• Surgery may be preferred in some cases, particularly if IBD is active or involves the rectum, though surgical complications are also increased.
• If radiation is chosen, modern techniques (IMRT, SBRT, brachytherapy) are preferred over older 3D conformal approaches.
• Patients should be counseled about the approximately 2-fold increased risk of IBD flare in the first year after radiation, while being reassured that serious complications are uncommon with modern techniques.

Part 6: Aggressive Histologic Variants

Most prostate cancers are adenocarcinomas — cancers of the glandular cells. But rarely, prostate cancer can take on different forms that behave very differently.

Small cell / neuroendocrine prostate cancer (NEPC):

This is the most important aggressive variant to understand. It can arise in two ways:

1. De novo: Rarely (less than 1% of prostate cancers), small cell carcinoma arises on its own without prior treatment.
2. Treatment-emergent (t-NEPC): More commonly (~15–17% of metastatic castration-resistant prostate cancer), prolonged androgen deprivation — especially with potent agents like enzalutamide or abiraterone — can cause the cancer to "switch" its identity from adenocarcinoma to a neuroendocrine phenotype. This is called lineage switching or transdifferentiation.

How to suspect NEPC:

• PSA may be low or even normal despite obvious disease progression — because neuroendocrine cells do not produce much PSA.
• The cancer grows rapidly, often involving the liver or other visceral organs (unusual for typical prostate adenocarcinoma).
• Markers such as LDH and CEA may be elevated.

Treatment of NEPC:

Because there are no large randomized trials specific to NEPC, treatment is largely borrowed from [small cell lung cancer](/rare-disease/small-cell-lung-cancer) protocols:

• Cisplatin or carboplatin combined with etoposide
• Docetaxel/carboplatin
• Cabazitaxel/carboplatin (for fit patients with aggressive variant features or unfavorable genomics — defects in at least 2 of PTEN, TP53, and RB1)

Other aggressive variants:

• Ductal adenocarcinoma: Often presents with higher stage and may have a worse prognosis than typical acinar adenocarcinoma.
• Sarcomatoid carcinoma: Extremely rare, aggressive, often resistant to standard therapies.
• Squamous cell carcinoma of the prostate: Very rare. Does not respond to hormone therapy. Treated with chemotherapy and/or radiation.
• Intraductal carcinoma (IDC-P): Not a separate variant per se, but a pathologic pattern associated with aggressive behavior and worse outcomes. Its presence on biopsy should prompt consideration of more aggressive treatment.

Part 7: Transitional Cell (Urothelial) Carcinoma Involving the Prostate

Sometimes what looks like prostate cancer is actually urothelial (transitional cell) carcinoma — the same type of cancer that arises in the bladder. It can involve the prostate in two ways:

• Direct extension from a bladder tumor growing into the prostate.
• Primary prostatic urethral origin — arising from the lining of the prostatic urethra.

Why does this matter?

The distinction is critical because urothelial carcinoma is treated completely differently from prostatic adenocarcinoma:

• Staging follows bladder cancer staging, not prostate cancer staging.
• Chemotherapy regimens are different (cisplatin-based combinations, immunotherapy).
• Hormone therapy, which is the backbone of advanced prostate adenocarcinoma treatment, does not work for urothelial carcinoma.

Correct pathologic diagnosis — often requiring immunohistochemistry stains — is essential to ensure the right treatment.

Part 8: Prostate Cancer in Gender-Diverse Individuals

Transgender women (male-to-female):

Transgender women retain their prostate regardless of whether they have undergone gender-affirming surgery (vaginoplasty). The prostate is not removed during vaginoplasty.

• Cancer risk: Feminizing hormone therapy (estrogen) has castrating effects that likely reduce — but do not eliminate — prostate cancer risk. The true incidence is unknown, but case reports suggest that when prostate cancer does occur in transgender women, it may present at a more advanced stage, possibly because of delayed screening or because the cancer may be castration-resistant from the outset.
• PSA screening: Gender-affirming hormones dramatically lower PSA levels. One study found a median PSA of only 0.02 ng/mL in transgender women on estrogen. This means that even a "normal-looking" PSA of 1.0 ng/mL in a transgender woman on hormones could be significantly elevated. A proposed upper limit of normal for transgender women on hormone therapy is 1.0 ng/mL.
• Screening rates are low. A retrospective study found that only 23% of transgender women aged 50 and older had ever received PSA screening.
• Treatment considerations: Both surgery and radiation require special planning due to altered anatomy after vaginoplasty. Multidisciplinary coordination with the patient's reconstructive surgeon is essential.

Transgender men (female-to-male): Do not have a prostate and are not at risk for prostate cancer.

Non-binary individuals: Risk depends on anatomy — those assigned male at birth who retain a prostate should undergo age-appropriate screening.

Creating a safe clinical environment:

• Use the patient's preferred name and pronouns.
• Understand that prostate-related discussions may cause gender dysphoria.
• Ensure that screening and treatment recommendations are based on anatomy, not gender identity.
• Recognize barriers to care: stigma, lack of provider knowledge, and insurance issues.

Part 9: Prostate Cancer in Men with Prior Pelvic Radiation

Some men develop prostate cancer after having previously received radiation therapy to the pelvis for another cancer — most commonly rectal cancer, bladder cancer, or lymphoma.

Key concerns:

• Cumulative dose: The pelvic tissues have already received radiation. Additional radiation to the prostate must account for the prior dose to avoid exceeding the tolerance of surrounding organs (rectum, bladder, urethra).
• Surgery may be preferred but is complicated by radiation-induced fibrosis and adhesions, which alter tissue planes and increase surgical risk.
• Modern techniques may allow safe retreatment. SBRT, HDR brachytherapy, and LDR brachytherapy have all been used for reirradiation in select cases.
• Second primary vs. radiation-induced cancer: A prostate cancer arising years after pelvic radiation could be a coincidental second primary (common, given the high prevalence of prostate cancer) or, rarely, a radiation-induced malignancy. The distinction does not usually change treatment but may be relevant for prognosis.

Key takeaway: Prior pelvic radiation does not make prostate cancer untreatable, but it does require an experienced multidisciplinary team to navigate the complexities of retreatment.

Part 10: Prostate Cancer and Kidney Transplant

Kidney transplant recipients face unique challenges when diagnosed with prostate cancer.

Key considerations:

• Immunosuppression and cancer risk: Transplant recipients are at least twice as likely to develop cancer compared to the general population due to chronic immunosuppression. However, prostate cancer specifically does not appear to be significantly more common or more aggressive in transplant recipients.
• Transplant kidney location: The transplanted kidney is typically placed in the iliac fossa (lower pelvis), directly in the potential radiation field. Radiation therapy must be carefully planned to minimize dose to the transplant kidney to avoid graft damage and ureteral stenosis.
• Surgery is feasible. Radical prostatectomy is the most commonly reported treatment in transplant recipients. Lymph node dissection is typically performed on the side opposite to the transplant kidney.
• Brachytherapy may be safe. Small series report that brachytherapy can be performed safely in transplant recipients without graft dysfunction.
• Active surveillance is appropriate for low-risk disease, just as in the general population.
• Drug interactions: Immunosuppressive medications may interact with cancer treatments. Coordination between the transplant team and oncology team is essential.

Part 11: Prostate Cancer and Hip Prosthesis

Hip replacement is increasingly common in the aging population, and many men with prostate cancer have one or both hips replaced.

Why does this matter for treatment?

• Imaging artifacts: Metal hip prostheses cause significant artifacts on CT scans, making it harder to see the prostate and surrounding structures clearly. MRI artifacts depend on the type of metal — titanium causes fewer artifacts than cobalt-chromium alloys.
• Radiation planning challenges: The metal prosthesis affects radiation dose calculation. Radiation beams passing through metal are attenuated unpredictably, creating dose uncertainty in the target and surrounding tissues.
• Planning strategies: Modern VMAT (volumetric modulated arc therapy) techniques can work around hip prostheses by using partial arcs that avoid the metal, or by using full arcs with dose constraints on the prostheses. Proton therapy using anterior beams or proton arc therapy has also been shown to be feasible.
• Bilateral prostheses are more challenging than unilateral, as there are fewer beam angles available that avoid both prostheses. However, modern planning techniques can still achieve adequate target coverage.

Key takeaway: Hip prostheses complicate radiation planning but do not prevent treatment. An experienced radiation oncology team with modern planning technology can deliver safe and effective treatment.

Part 12: Prostate Cancer in Men with HIV

With modern antiretroviral therapy (ART), people living with HIV (PLWH) now have near-normal life expectancies, making age-related cancers like prostate cancer increasingly relevant.

Screening:

Prostate cancer screening recommendations for men with HIV are the same as for the general population — follow USPSTF or ACS guidelines.

Treatment:

• Standard-of-care treatment for localized prostate cancer — surgery, radiation, active surveillance — is appropriate for men with well-controlled HIV.
• CD4 count monitoring: Radiation therapy may cause a decline in CD4 counts. More frequent monitoring may be needed during and after treatment.
• Drug interactions: ART medications — particularly protease inhibitors and some NNRTIs — can interact with cancer treatments. INSTI-based ART regimens are preferred because they have fewer drug-drug interactions.
• Cancer treatment should not be delayed for HIV workup, and ART should be continued during cancer therapy.

Part 13: Prostate Cancer in Men with Bleeding Disorders or on Anticoagulation

Men on blood thinners (warfarin, direct oral anticoagulants, antiplatelet agents) or with bleeding disorders ([hemophilia](/rare-disease/hemophilia), [von Willebrand disease](/rare-disease/von-willebrand-disease)) face practical challenges at multiple points in the prostate cancer journey:

• Biopsy: Blood thinners typically need to be held before prostate biopsy to reduce bleeding risk. The transperineal approach may have a lower bleeding risk than the transrectal approach. Coordination with the prescribing physician (often a cardiologist) is essential to determine the safety of temporarily stopping anticoagulation.
• Fiducial marker placement: Small gold markers placed in the prostate before radiation therapy require a needle procedure similar to biopsy, with similar bleeding considerations.
• Surgery: Radical prostatectomy carries a risk of bleeding, and anticoagulation management in the perioperative period requires careful planning.
• Radiation: Once treatment is underway, radiation itself does not require stopping blood thinners. However, radiation can cause delayed bleeding (hematuria, rectal bleeding) that may be more problematic in anticoagulated patients.

Key takeaway: Bleeding disorders and anticoagulation require careful coordination but do not prevent prostate cancer treatment.

Part 14: Prostate Cancer in Men with Psychiatric Illness or Cognitive Impairment

Men with significant psychiatric illness (severe depression, schizophrenia, bipolar disorder) or cognitive impairment (dementia, intellectual disability) face unique challenges:

• Decision-making capacity: Treatment decisions for prostate cancer are complex and require understanding of risks, benefits, and alternatives. If a patient lacks capacity, a healthcare proxy or legal guardian must be involved.
• Treatment compliance: Active surveillance requires regular follow-up visits, PSA tests, and repeat biopsies. Radiation therapy requires daily treatments for several weeks. If compliance is a concern, simpler treatment approaches (such as surgery as a one-time intervention, or shorter radiation courses like SBRT) may be preferred.
• Caregiver involvement: Family members or caregivers play a critical role in ensuring appointments are kept, medications are taken, and side effects are reported.
• Psychiatric medication interactions: Some psychiatric medications (particularly those affecting the QT interval) may interact with hormone therapy agents. Coordination with the psychiatrist is important.
• Overtreatment risk: In men with severe dementia and limited life expectancy, observation may be the most appropriate approach, even for intermediate-risk disease.

Part 15: Prostate Cancer Discovered Incidentally

Sometimes prostate cancer is found unexpectedly:

• During TURP for BPH: Cancer found in TURP specimens is classified as T1a (≤5% of tissue, low grade) or T1b (>5% or higher grade). T1a cancers in older men often require no further treatment. T1b cancers generally warrant further evaluation with PSA, imaging, and possibly additional biopsy.
• During imaging for another condition: A suspicious prostate lesion may be found on a CT or MRI performed for an unrelated reason (back pain, abdominal symptoms). This requires follow-up with PSA testing and possibly MRI-targeted biopsy.
• Autopsy studies: Research has shown that 20–30% of men aged 40–50 have microscopic prostate cancer found at autopsy, and the prevalence increases with age. The vast majority of these cancers would never have caused symptoms or death.⁷ This underscores the importance of not overtreating low-risk disease.

Part 16: Challenging Anatomy for Radiation Therapy

Beyond hip prostheses, several anatomic situations create challenges for radiation planning:

• Severe scoliosis: Spinal curvature can shift pelvic anatomy and make standard beam arrangements suboptimal. Custom planning with non-standard beam angles may be needed.
• Prior spinal hardware: Metal rods and screws in the lumbar spine can cause imaging artifacts and dose calculation uncertainty, similar to hip prostheses.
• Morbid obesity: Very large body habitus increases the distance radiation must travel to reach the prostate, potentially affecting dose delivery. Larger patients may not fit in standard CT simulators or MRI machines. Treatment couches have weight limits. Despite these challenges, modern techniques can usually accommodate larger patients, though setup reproducibility may be reduced.

Part 17: What If I Choose No Treatment?

This is a question many men ask, and it deserves an honest answer. The outcome of doing nothing depends entirely on the risk group of the cancer.

Low-risk prostate cancer (Gleason 6 / Grade Group 1):

The natural history is very favorable. A comprehensive review found that Grade Group 1 tumors have less than 5% risk of metastasis over 15–20 years.⁸ The ProtecT trial, which randomized men with mostly low-risk, screen-detected prostate cancer to active monitoring, surgery, or radiation, found that prostate cancer mortality was approximately 1% at 10 years regardless of treatment group.¹⁷ At 15 years, there was still no significant difference in prostate cancer mortality among the three groups, and 24.4% of men in the active monitoring group were alive without ever having received treatment.¹⁸ A large multicenter active surveillance study of 2,155 patients confirmed that at 10 years, less than 2% developed metastases and less than 1% died of prostate cancer.¹⁹

Active surveillance — which is structured monitoring with intent to treat if the cancer progresses — is the recommended approach for low-risk disease. The NCCN notes that approximately 50% of those eligible for active surveillance may safely avoid treatment for 10 years.²⁰

Intermediate-risk prostate cancer:

Outcomes are more variable. Some intermediate-risk cancers behave like low-risk disease, while others progress over 10–15 years. The ProtecT trial showed that men on active monitoring had higher rates of metastasis (9.4% at 15 years) compared to surgery (4.7%) or radiation (5.0%), though this did not translate into a significant difference in cancer-specific death.¹⁸ A long-term study of Gleason score performance found that the 10-year risk of lethal disease was 2% for Grade Group 2 cancers, rising to 5% by 25 years.²¹

High-risk prostate cancer:

Untreated high-risk disease carries significant risk. A review of long-term outcomes found that Grade Groups 4–5 tumors exhibit rapid progression with median disease-specific survival of less than 5 years if untreated.⁸ The 10-year risk of lethal disease for Grade Group 5 was 21%, rising to 32% by 25 years.²¹ The SPCG-4 trial, which included men with mostly clinically detected (not screen-detected) prostate cancer, showed that surgery reduced prostate cancer death by 44% compared to watchful waiting over 30 years of follow-up, with the number needed to treat decreasing from 58 at 5 years to just 6 at 30 years.²²

The bottom line:

• For low-risk disease: doing nothing (with monitoring) is often the right choice.
• For intermediate-risk disease: treatment is generally recommended, but the urgency depends on specific features.
• For high-risk disease: treatment is strongly recommended. Choosing no treatment carries a meaningful risk of cancer progression and death.

Myth vs. Fact

• Myth: "Young men do not get prostate cancer."

Fact: Approximately 1–4.5% of prostate cancers occur in men under 50, and the incidence has been rising globally.¹ ²

• Myth: "If you are old, you must treat it."

Fact: Many older men with low-risk prostate cancer benefit most from observation. Competing mortality from non-cancer causes substantially exceeds cancer-specific mortality in men over 75.⁸ ⁹

• Myth: "Transgender women cannot get prostate cancer."

Fact: The prostate remains after gender-affirming surgery. Although risk may be reduced by feminizing hormones, it is not eliminated.

• Myth: "Aggressive variants are always fatal."

Fact: Outcomes vary. Mixed histology neuroendocrine tumors fare better than pure small cell, and treatment options are expanding.

• Myth: "If I had prior pelvic radiation, nothing can be done."

Fact: Modern reirradiation techniques (SBRT, HDR brachytherapy) can safely treat prostate cancer even after prior pelvic radiation in select patients.

• Myth: "Hip replacements make radiation impossible."

Fact: Modern VMAT and proton therapy techniques can deliver safe, effective radiation around hip prostheses.

• Myth: "Men with HIV should not receive standard cancer treatment."

Fact: Standard-of-care treatment is appropriate for men with well-controlled HIV, with co-management by an HIV specialist.

• Myth: "Men with IBD cannot receive radiation."

Fact: Modern radiation techniques (SBRT, IMRT) appear safe in IBD patients, with serious complications being uncommon.¹³ ¹⁴

Questions to Ask Your Doctor

If you are a young man:

• Should I bank sperm before treatment?
• Should I (and my family members) undergo genetic testing?
• How will treatment affect my fertility and sexual function over the long term?

If you are an older man:

• What is my estimated life expectancy considering my other health conditions?
• Would observation be a reasonable option for my cancer?
• What are the risks of treatment side effects at my age?

If you have had a prior TURP:

• Does my prior TURP affect which radiation techniques can be used?
• Am I still a candidate for brachytherapy?

If you have IBD:

• Is my IBD well enough controlled to safely receive radiation?
• Should my gastroenterologist be involved in treatment planning?

If you are a transgender woman:

• How should my PSA be interpreted given my hormone therapy?
• How will my anatomy after vaginoplasty affect treatment options?

If you have a hip prosthesis:

• Does your radiation planning team have experience treating patients with hip prostheses?
• Would proton therapy be an option for me?

If you have HIV:

• Will my ART medications interact with cancer treatment?
• How often should my CD4 count and viral load be monitored during treatment?

If you have a kidney transplant:

• How will radiation be planned to protect my transplant kidney?
• Should my transplant team be involved in treatment decisions?

If you are considering no treatment:

• What is the natural history of my specific cancer if left untreated?
• What is the difference between active surveillance and watchful waiting?
• At what point would you recommend I reconsider treatment?

Key Takeaways

1. No two patients are the same — special circumstances require individualized treatment plans.
2. Young men should prioritize fertility preservation and genetic testing; older men should focus on life expectancy and competing risks, not age alone.
3. Prior TURP, absent rectum, IBD, hip prostheses, and kidney transplant all require special planning but do not prevent treatment.
4. Aggressive variants (small cell, ductal) require different treatment strategies — correct pathologic diagnosis is critical.
5. Gender-diverse individuals deserve inclusive, knowledgeable care — the prostate does not disappear after transition.
6. For low-risk disease, choosing no immediate treatment (with monitoring) is often the right choice. For high-risk disease, treatment is strongly recommended.
7. Men with HIV, bleeding disorders, psychiatric illness, or cognitive impairment can and should receive appropriate cancer care with multidisciplinary coordination.

Support Resources

For young men:

• ZERO — The End of Prostate Cancer: Young Men's Support Program (zerocancer.org)
• Livestrong Fertility (livestrong.org/fertility) — fertility preservation resources and financial assistance
• Stupid Cancer (stupidcancer.org) — support community for young adults with cancer

For older men:

• Cancer and Aging Research Group (mycarg.org) — geriatric oncology resources
• National Institute on Aging (nia.nih.gov) — aging and health information

For gender-diverse individuals:

• National LGBT Cancer Network (cancer-network.org) — culturally competent cancer care resources
• GLMA: Health Professionals Advancing LGBTQ+ Equality (glma.org) — provider directory
• TransLifeline (translifeline.org) — peer support hotline

For men with IBD:

• Crohn's & Colitis Foundation (crohnscolitisfoundation.org) — IBD management resources
• IBD and Cancer Support Group — available through many academic medical centers

For men with HIV:

• National Association of People with AIDS (napwa.org)
• AIDS.gov — treatment and support resources
• The Well Project (thewellproject.org) — HIV and cancer co-management information

For transplant recipients:

• American Society of Transplantation (myast.org) — patient resources
• Transplant Living (transplantliving.org) — life after transplant, including cancer screening

For all patients:

• Prostate Cancer Foundation (pcf.org) — comprehensive education and support
• Us TOO International (ustoo.org) — peer-to-peer support groups
• American Cancer Society (cancer.org) — treatment information, financial assistance, lodging programs
• CancerCare (cancercare.org) — free counseling, support groups, financial assistance
• Patient Advocate Foundation (patientadvocate.org) — insurance and financial navigation

References

1. 1. Baniak, N. et al. Clinicopathological and molecular characteristics of prostate cancer diagnosed in young men aged up to 45 years. Histopathology 78, 857–870 (2021).
2. 2. Bleyer, A., Spreafico, F. & Barr, R. Prostate cancer in young men: an emerging young adult and older adolescent challenge. Cancer 126, 46–57 (2020).
3. 3. Pinsky, P. F. & Parnes, H. Screening for prostate cancer. N. Engl. J. Med. 388, 1405–1414 (2023).
4. 4. Zheng, Y. et al. Clinicopathological characteristics of localized prostate cancer in younger men aged ≤50 years treated with radical prostatectomy in the PSA era: a systematic review and meta-analysis. Cancer Med. 9, 6473–6484 (2020).
5. 5. Mahal, A. R. et al. Conservative management of low-risk prostate cancer among young versus older men in the United States: trends and outcomes from a novel national database. Cancer 125, 3338–3346 (2019).
6. 6. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 2.2026.
7. 7. Litwin, M. S. & Tan, H. J. The diagnosis and treatment of prostate cancer: a review. JAMA 317, 2532–2542 (2017).
8. 8. Tewari, A. K. et al. Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes. Prostate Cancer Prostatic Dis. (2026). doi:10.1038/s41391-026-01095-7.
9. 9. Ventimiglia, E. et al. Natural history of nonmetastatic prostate cancer managed with watchful waiting. JAMA Netw. Open 7, e2414599 (2024).
10. 10. National Comprehensive Cancer Network. Prostate Cancer. Version 5.2026.
11. 11. Patel, P. et al. Association between inflammatory bowel disease and prostate cancer: a large-scale genetic and observational study. J. Clin. Oncol. 44 (suppl 16; abstr e17136) (2026).
12. 12. Burns, J. A. et al. Inflammatory bowel disease is associated with an increased risk of prostate cancer development: a retrospective matched cohort study. J. Urol. 211, 73–80 (2024).
13. 13. Blacksburg, S. R. et al. Radiation therapy for prostate cancer in patients with inflammatory bowel disease: a multicenter Veterans Affairs study. Adv. Radiat. Oncol. 8, 101131 (2023).
14. 14. Kishan, A. U. et al. Stereotactic body radiation therapy for prostate cancer in patients with inflammatory bowel disease. Int. J. Radiat. Oncol. Biol. Phys. 112, 912–920 (2022).
15. 15. Patel, S. et al. Impact of inflammatory bowel disease on outcomes following radical prostatectomy: a National Inpatient Sample analysis. Urology 175, 120–127 (2023).
16. 16. Ananthakrishnan, A. N. et al. AGA Clinical Practice Update on management of inflammatory bowel disease in patients with a history of cancer. Gastroenterology 166, 920–931 (2024).
17. 17. Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).
18. 18. Hamdy, F. C. et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 388, 1547–1558 (2023).
19. 19. Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272–277 (2015).
20. 20. Fonteyne, V. et al. Prostate cancer. Lancet 407, 622–636 (2026).
21. 21. Dess, R. T. et al. Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 6, 1912–1920 (2020).
22. 22. Holmberg, L. et al. Time dependence of outcomes in the SPCG-4 randomized trial comparing radical prostatectomy and watchful waiting in early prostate cancer. Eur. Urol. (2025). doi:10.1016/j.eururo.2025.07.001.